Navigation Links
Fox Chase Cancer Center receives $8 million NIH grant to expand laboratory animal research facility
Date:9/2/2009

PHILADELPHIA (September 2, 2009) The Fox Chase Cancer Center has received an $8 million grant from the National Center for Research Resources of the National Institutes of Health (NCRR/NIH) to expand their laboratory animal research facility. The new facility will support advanced research into the fundamental biological processes underlying cancer, opening the way for the development of new treatments. The funds for the grant were made available through the American Recovery and Reinvestment Act.

According to the Fox Chase administration, construction of the facility, which will house mouse models for cancer research, should begin within a year. The four-story, 25,290 square-foot space will be built alongside and serve as an expansion to the existing animal facility on the Fox Chase campus. The plans entail using the top two floors, roughly 12,910 square feet, for new animal research space, reserving the remaining two floors for support areas and future expansion. The new facility will include high efficiency particulate air (HEPA) ventilation systems and improved support for the state-of-the-art animal care equipment of the sort already being utilized on campus.

"While the current facilities are entirely adequate for the care and feeding of the animal models they house, they are simply not large enough or sophisticated enough to meet the needs of Fox Chase's expanding research faculty," says Harry Rozmiarek, D.V.M., Ph.D., director of the laboratory animal medicine program. "Many of the mice are immunodeficient, and require a special environment with filtered air to keep them from becoming infected by otherwise normal bacterial flora."

Rozmiarek joined Fox Chase in 2004 and initiated a long-range plan at that time to expand and improve the animal research facilities at Fox Chase. "Since then, we have consolidated as much as possible to make more space available for research mice, improved and modernized the animal research facility, and began to systematically convert standard caging and racks to high-density individually ventilated cages." Rozmiarek says. "This expansion is essential to complete the plan and will permit the high quality research at Fox Chase to continue to improve and expand."

"We are grateful that NIH recognizes the need to strengthen basic science infrastructure, and that it has the funding to do so," says Michael V. Seiden, MD, PhD, president and CEO of Fox Chase Cancer Center. "Without such facilities, biomedical research would be impossible and advances in medicine would simply stop moving forward in all fields."


'/>"/>

Contact: Greg Lester
gregory.lester@fccc.edu
215-728-2753
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. RainEarth (RNER) Signs Purchase Agreement with HangZhou Municipal No.3 Peoples Hospital
2. Winner Medical Purchased New Purcotton Production Line to Meet Increasing Demand
3. Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares
4. Wasting Millions on Purchases Based on Physician Preference White Paper Now Available From ECRI Institute
5. Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2009 Results and Announces Share Repurchase
6. DaVita Only Dialysis Provider Named on EPAs FORTUNE 500 List of Green Power Purchasers
7. Fox Chase finds that lung cancer patients respond to erlotinib following cetuximab therapy
8. Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients
9. Fox Chase researchers identify differences in treatments and outcomes of patients with second primary lung cancers versus those with one primary lung cancer
10. Nutraceutical Reports Fiscal 2009 Q3 Results and Expands Share Repurchase Program
11. Patriot Scientific Corporation Announces Cardiac Science Corporations Purchase of a Moore Microprocessor Patent(TM) Portfolio License
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... KS (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com ... leader in Mole removal products. , Moles are derived from a cluster of melanin ... in all the wrong places and create a lifetime of embarrassment. Historically, mole ...
(Date:2/8/2016)... ... 08, 2016 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase patient awareness of ... Your Mouth?” campaign to inform dentists and patients about the possible lack of ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... Plastics, has added Kybella® to his medical and surgical expertise. Technically known as ... FDA injectable medication used as a non-surgical alternative for reduction of fat below ...
(Date:2/6/2016)... St. Petersburg, FL (PRWEB) , ... February 06, 2016 , ... ... AsSeenOnTV.pro are pleased to announce the launch of a new DRTV campaign with Belly ... rug. If having tried everything from sprays to puppy pads and find nothing works, ...
(Date:2/5/2016)... ... 05, 2016 , ... VeloReality President and co-founder ... LYNX VR Indoor Trainer with multi-rider capability to an enthusiastic audience at the ... reduce the weight of the unit, they also enhance the rider's experience with ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 4, 2016  The Senior Care Pharmacy Coalition ... Committee Chairman Jason Chaffetz (R-UT) and ... hearing , "Developments in the Prescription Drug ... growing questions about abusive pharmacy benefit manager (PBM) ... and Ranking Member Elijah Cummings (D-MD) are diligent, ...
(Date:2/4/2016)... , Feb. 4, 2016   Bernstein Liebhard LLP ... in the United States District Court for the District of ... (the "Class") consisting of all persons or entities who purchased ... (NASDAQ: INSY ) from March 3, 2015 through January ... certain of its officers with violations of the Securities Exchange ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
Breaking Medicine Technology: